U.S. Markets closed
  • S&P 500

    3,635.41
    +57.82 (+1.62%)
     
  • Dow 30

    30,046.24
    +454.97 (+1.54%)
     
  • Nasdaq

    12,036.79
    +156.15 (+1.31%)
     
  • Russell 2000

    1,853.53
    +35.23 (+1.94%)
     
  • Crude Oil

    44.78
    -0.13 (-0.29%)
     
  • Gold

    1,805.20
    +0.60 (+0.03%)
     
  • Silver

    23.28
    -0.02 (-0.09%)
     
  • EUR/USD

    1.1902
    +0.0006 (+0.0476%)
     
  • 10-Yr Bond

    0.8820
    +0.0250 (+2.92%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3363
    +0.0005 (+0.0374%)
     
  • USD/JPY

    104.4870
    +0.0070 (+0.0067%)
     
  • BTC-USD

    19,138.56
    +18.26 (+0.10%)
     
  • CMC Crypto 200

    380.50
    +10.75 (+2.91%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,632.82
    +467.23 (+1.79%)
     

Pacific Biosciences: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Pacific Biosciences (NASDAQ:PACB) fell 8.6 in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 26.32% year over year to ($0.14), which missed the estimate of ($0.13).

Revenue of $19,082,000 decreased by 12.93% from the same period last year, which missed the estimate of $20,350,000.

Looking Ahead

Pacific Biosciences hasn't issued any earnings guidance for the time being.

Pacific Biosciences hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 02, 2020

View more earnings on PACB

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/n52bxqin

Price Action

Company's 52-week high was at $15.12

52-week low: $2.20

Price action over last quarter: Up 208.48%

Company Description

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.